---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-028914"
form_type: "8-K"
ticker: "SEER"
cik: "0001726445"
company_name: "Seer, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:07:16.196871+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Seer Q3 revenue $4.0M, net loss $24.0M; FY2022 guidance reaffirmed

## Summary
- Revenue of $4.0M, up 82% YoY from $2.2M, driven by Proteograph product suite sales.
- Net loss of $24.0M vs $18.4M in Q3 2021; operating expenses $27.0M including $9.1M stock-based comp.
- Gross margin 49%; cash, cash equivalents and investments $441.0M at Sep 30, 2022.
- Full-year 2022 revenue guidance reaffirmed at $14.0M to $16.0M.
- Published results in Advanced Materials; customer adoption increasing with multiple studies underway.

## SEC filing metadata
- accession: 0001628280-22-028914
- form_type: 8-K
- ticker: SEER
- cik: 0001726445
- company_name: Seer, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726445/000162828022028914/0001628280-22-028914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726445/000162828022028914/seer-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-028914
- JSON: https://secwatch.observer/filing/0001628280-22-028914.json
- Plain text: https://secwatch.observer/filing/0001628280-22-028914.txt

## Key facts
- Earnings Releases
  Seer, Inc. reported the third quarter ended September 30, 2022 results: revenue $4.0 million, net income $24.0 million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $4.0 million
  - Net income: $24.0 million
  - Result: reported results
  source text: Revenue was $4.0 million for the three months ended September 30, 2022, as compared to $2.2 million for the three months ended September 30, 2021. The increase was primarily due to increased sales of the Proteograph Product Suite and its related products. Product-related revenue for the third quarter of 2022 was $3.9 million, including $1.3 million of related party revenue, and consisted of sales of SP100 instruments, consumable kits and platform evaluations. Gross profit was $1.9 million and gross margin was 49% for the third quarter of 2022. Operating expenses were $27.0 million for the third quarter of 2022, including $9.1 million of stock-based compensation, as compared to $19.6 million, including $6.8 million of stock-based compensation, for the corresponding prior year period. The increase in expenses was driven by increased employee compensation and other related expenses, including stock-based compensation, and increased expenses related to the expansion of the company’s facili
  evidence_url: https://www.sec.gov/Archives/edgar/data/1726445/000162828022028914/0001628280-22-028914-index.htm
- Earnings Releases
  Seer, Inc. updated its full year 2022 guidance (reaffirmed).
  - Period: full year 2022
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Seer continues to expect full year 2022 revenue to be in the range of $14.0 million to $16.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1726445/000162828022028914/0001628280-22-028914-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.